SecBot SecBot

Facilitating Innovative Nuclear Diagnostics Act of 2023

H.R. 1199 Rep. Neal Dunn (R-FL-2) In committee
Bill text PDF
  1. Introduced Feb 27
  2. Committee Feb 27
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Feb 27, 2023Next: House vote
895d ago May 16, 2024: Forwarded by Subcommittee to Full Committee by Voice Vote.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
4companies, 4 filings
Subscribe to see spend
Member trades
1trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

4 companies
Companies by sector
Medical Devices & Healthcare 2Biotech & Pharma 1Other 1
Search all 4 companies, their asks and price moves Subscribe

Summary

Facilitating Innovative Nuclear Diagnostics Act of 2023

Full summary1 paragraphs

This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2024 and as adjusted based on a specified fee schedule factor in each year thereafter.

Library of Congress summary, Feb 27, 2023

Summary versions
  • Introduced in HouseFeb 27, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.